Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Src signaling was considered a potential mechanism of resistance to androgen-targeted therapy. In a randomized trial, we studied whether the addition of dasatinib would delay prostate cancer progression compared with abiraterone alone. Progression-free survival was not prolonged, although there were...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Genitourin Cancer
Egile Nagusiak: Dorff, Tanya B., Quinn, David I., Pinski, Jacek K., Goldkorn, Amir, Sadeghi, Sarmad, Tsao-Wei, Denice, Groshen, Susan, Kuhn, Peter, Gross, Mitchell E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446934/
https://ncbi.nlm.nih.gov/pubmed/31227432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.02.010
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak